Abstract
Objectives: This is a protocol for a Cochrane Review (intervention). The objectives are as follows:. To assess the benefits and harms of systemic pharmacological interventions for Ménière's disease.
| Original language | English |
|---|---|
| Article number | CD015171 |
| Journal | Cochrane Database of Systematic Reviews |
| Volume | 2021 |
| Issue number | 12 |
| DOIs | |
| Publication status | Published - 31 Dec 2021 |
Access to Document
Other files and links
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: Cochrane Database of Systematic Reviews, Vol. 2021, No. 12, CD015171, 31.12.2021.
Research output: Contribution to journal › Review article › Academic › peer-review
TY - JOUR
T1 - Systemic pharmacological interventions for Ménière’s disease
AU - Webster, Katie E.
AU - Harrington-Benton, Natasha A.
AU - Judd, Owen
AU - Kaski, Diego
AU - Maarsingh, Otto R.
AU - MacKeith, Samuel
AU - Ray, Jaydip
AU - Van Vugt, Vincent A.
AU - Burton, Martin J.
N1 - Funding Information: This project was supported by the National Institute for Health Research, via Cochrane Infrastructure, Cochrane Programme Grant or Cochrane Incentive funding to Cochrane ENT, as well as an Evidence Synthesis Programme grant (NIHR132217). The views and opinions expressed therein are those of the authors and do not necessarily reflect those of the Systematic Reviews Programme, NIHR, NHS or the Department of Health. The development of the protocol (including the prioritisation of outcomes) for this review was informed by responses to a survey to encourage patient and public involvement in the review process. The development and distribution of this survey would not have been possible without the support of the M?ni?re's Society and the Migraine Trust, and the authors wish to thank them for their help. The authors would like to thank Lee Yee Chong for her work on generic text that has been used and adapted (with permission) in the methods section of this protocol. We would also like to extend our thanks to Frances Kellie and Cochrane Pregnancy and Childbirth for their permission to use and reproduce the Cochrane Pregnancy and Childbirth Trustworthiness Screening Tool in this review. The authors are grateful to Mr Malcolm Hilton for peer review of this protocol and the others in the M?ni?re's disease series, to Francesca Edwards for her consumer review and to Anne Littlewood, Information Specialist with Cochrane Oral Health, for providing peer review comments on the draft search methods. Many thanks, lastly, to Professor Peter Tugwell for the editorial sign-off of this protocol and the others in the series. Funding Information: This project was supported by the National Institute for Health Research, via Cochrane Infrastructure, Cochrane Programme Grant or Cochrane Incentive funding to Cochrane ENT, as well as an Evidence Synthesis Programme grant (NIHR132217). The views and opinions expressed therein are those of the authors and do not necessarily reflect those of the Systematic Reviews Programme, NIHR, NHS or the Department of Health. Publisher Copyright: Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
PY - 2021/12/31
Y1 - 2021/12/31
N2 - Objectives: This is a protocol for a Cochrane Review (intervention). The objectives are as follows:. To assess the benefits and harms of systemic pharmacological interventions for Ménière's disease.
AB - Objectives: This is a protocol for a Cochrane Review (intervention). The objectives are as follows:. To assess the benefits and harms of systemic pharmacological interventions for Ménière's disease.
UR - http://www.scopus.com/inward/record.url?scp=85122059391&partnerID=8YFLogxK
U2 - https://doi.org/10.1002/14651858.CD015171
DO - https://doi.org/10.1002/14651858.CD015171
M3 - Review article
SN - 1465-1858
VL - 2021
JO - Cochrane Database of Systematic Reviews
JF - Cochrane Database of Systematic Reviews
IS - 12
M1 - CD015171
ER -